German contract manufacturers invest €70 million on expansions

Contract manufacturer IDT Biologika and a related company, Oncotec Pharma Produktion, are putting a combined €70 million into plants at IDT's BioPharmaPark in Dessau-Roβlau, Germany. IDT will invest €40 million in its vaccine and parenteral sterile fill-and-finish capacities. The upgrades will include serialization and anticounterfeiting capabilities. In September it started production resulting from an earlier expansion project that has increased its vial-production capacity to 60 million units per year. Oncotec is investing €30 million to expand sterile parenteral oncology drug manufacturing capacity. Spokesman Peter Kellner said in an email that IDT Biologika is part of the Klocke Group, owned by the Klocke family. The Klocke Group also has a 50% ownership in Oncotec. The other half is held by the German company MEDAC. Announcement